原研机构 |
非在研机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)临床1期 |
特殊审评- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
镰状细胞血症 | 临床1期 | 中国 | 2024-09-02 | |
β地中海贫血 | 临床1期 | 中国 | 2024-04-18 |
临床1期 | 6 | 窪蓋壓顧獵範壓蓋顧鬱(選廠襯餘繭簾觸夢襯獵) = All participants had ≥1 adverse event (AE) of Grade 3 or 4 severity (including laboratory-based AEs). The most three common Grade 3 or 4 AEs were neutrophil count decreased (100%), platelet count decreased (100%), and white blood cell decreased (100%). Most AEs were commonly observed after myeloablative busulfan conditioning and no AEs were reported as related to CS-101 in the 6 patients. 簾醖顧鬱窪積憲壓獵窪 (夢膚獵衊鹽窪鏇廠網選 ) 更多 | 积极 | 2024-12-09 | |||
N/A | - | 3 | 蓋鑰獵積願遞製積遞窪(鏇餘範壓遞蓋鏇鹽鹹襯) = No SAEs were reported up to the cut-off date 選獵蓋獵衊廠鬱壓膚廠 (簾鏇餘壓選遞鬱簾願鹹 ) 更多 | 积极 | 2024-05-14 | ||
临床1期 | 1 | 範鬱艱範獵獵衊顧膚繭(製襯顧鬱醖夢襯糧製壓) = 範鏇憲顧廠鬱鏇鏇築膚 觸遞簾製製構壓窪觸糧 (鹽窪鑰積夢獵憲壓繭窪 ) | 积极 | 2024-01-08 |